Association of genetically enhanced lipoprotein lipase-mediated lipolysis and low-density lipoprotein cholesterol-lowering alleles with risk of coronary disease and type 2 diabetes
<strong>Importance</strong> Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs...
Päätekijät: | Lotta, L, Stewart, I, Sharp, S, Day, F, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, L, Kerrison, N, Khaw, K, McCarthy, M, O'Rahilly, S, Scott, R, Savage, D, Perry, J, Langenberg, C, Wareham, N |
---|---|
Aineistotyyppi: | Journal article |
Kieli: | English |
Julkaistu: |
American Medical Association
2018
|
Samankaltaisia teoksia
-
Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes
Tekijä: Lotta, LA, et al.
Julkaistu: (2018) -
Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis
Tekijä: Lotta, L, et al.
Julkaistu: (2016) -
Effect of pancreas transplantation on lipoprotein lipase, postprandial lipemia, and HDL cholesterol.
Tekijä: Föger, B, et al.
Julkaistu: (1994) -
Human triacylglycerol-rich lipoprotein subfractions as substrates for lipoprotein lipase.
Tekijä: Fisher, R, et al.
Julkaistu: (1995) -
Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein.
Tekijä: Karpe, F, et al.
Julkaistu: (1993)